Table 1.

Somatic variations identified in five AML patients.

Case	Somatic mutations present in leukemia and residual HSCs	Leukemia-specific somatic mutations
SU008	SKP2, PDZD3, ELP2	SEMA5A, OR4A47, CNDP1, ISYNA1, FLT3
SU014	NPM1, SMC1A, KAISO, SMG7, SLC22A10	NUP210, USP13, SMPD3, IDH1, FLT3
SU030	KCTD4	SLC12A1, FLT3
SU048	TET2 (biallelic), SMC1A, ACSM1, FKBP9L, GOLGA7B, NPHP4, OLFM2, ZMYM3	RHCG, FLT3
SU070	TET2 (biallelic), CTCF, PLA2G4D, CXorf36, KALRN, GZF1, CACNA1H, CXorf66, PRPF6, SCN4B, GABARAPL1, NcRNA00200, DOCK9	TMEM8B, TMEM20, PXDN, ZRANB1, FLT3
Total	32 (7)	19 (6)

Recurrent mutations.

Mutations in genes with RPKM gene expression <0.1.

Sanger re-sequencing of leukemia DNA and CD3⁺ T cell DNA confirmed all of the listed variations as somatic mutations. RNA sequencing was performed on bulk AML cells for leukemic samples SU008, SU014, SU030, and SU048 to determine which variations were expressed at a level of reads per kilobase of transcript per million mapped reads > 0.1.